Randomized trial shows high-dose VX-548 reduces acute pain after abdominoplasty or bunionectomy, indicating efficacy of selective Nav1.8 inhibition.
As compared with placebo, VX-548 at the highest dose, but not at lower doses, reduced acute pain over a period of 48 hours after abdominoplasty or bunionectomy. VX-548 was associated with adverse events that were mild to moderate in severity. (Funded by Vertex Pharmaceuticals; VX21-548-101 and VX21-548-102 ClinicalTrials.gov numbers, NCT04977336 and NCT05034952.).
No takes yet. Share an insight, caveat, or question.
Jones et al. (2023) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: